BlackRock Institutional Trust Company N.A. lowered its position in FibroGen Inc. (NASDAQ:FGEN) by 1.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,217,068 shares of the biopharmaceutical company’s stock after selling 23,655 shares during the period. BlackRock Institutional Trust Company N.A. owned about 1.98% of FibroGen worth $25,911,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in FGEN. Visium Asset Management LP increased its stake in FibroGen by 1.0% in the fourth quarter. Visium Asset Management LP now owns 2,031,936 shares of the biopharmaceutical company’s stock worth $61,913,000 after buying an additional 20,836 shares during the period. BlackRock Fund Advisors increased its stake in FibroGen by 2.7% in the first quarter. BlackRock Fund Advisors now owns 1,956,290 shares of the biopharmaceutical company’s stock worth $41,649,000 after buying an additional 51,957 shares during the period. Price T Rowe Associates Inc. MD increased its stake in FibroGen by 0.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 929,067 shares of the biopharmaceutical company’s stock worth $28,309,000 after buying an additional 5,230 shares during the period. Bank of America Corp DE increased its stake in FibroGen by 910.6% in the fourth quarter. Bank of America Corp DE now owns 422,884 shares of the biopharmaceutical company’s stock worth $12,885,000 after buying an additional 381,039 shares during the period. Finally, Highland Capital Management LP purchased a new stake in FibroGen during the fourth quarter worth approximately $12,612,000.
Shares of FibroGen Inc. (NASDAQ:FGEN) traded up 1.23% on Thursday, reaching $18.93. The company had a trading volume of 308,902 shares. The company’s 50-day moving average price is $16.92 and its 200 day moving average price is $18.56. The firm’s market capitalization is $1.18 billion. FibroGen Inc. has a 52 week low of $14.38 and a 52 week high of $31.90.
A number of equities research analysts recently commented on FGEN shares. Credit Suisse Group AG reaffirmed a “buy” rating on shares of FibroGen in a report on Tuesday, July 12th. Zacks Investment Research raised FibroGen from a “sell” rating to a “hold” rating in a report on Tuesday, May 10th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. FibroGen presently has a consensus rating of “Buy” and an average target price of $33.50.
In other FibroGen news, CEO Thomas B. Neff sold 37,798 shares of the stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $18.38, for a total transaction of $694,727.24. Following the completion of the sale, the chief executive officer now directly owns 3,413,255 shares of the company’s stock, valued at approximately $62,735,626.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Thomas B. Neff sold 27,000 shares of the stock in a transaction that occurred on Tuesday, May 3rd. The stock was sold at an average price of $17.78, for a total value of $480,060.00. Following the sale, the chief executive officer now directly owns 3,552,353 shares of the company’s stock, valued at $63,160,836.34. The disclosure for this sale can be found here.
FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
